News | Focused Ultrasound Therapy | April 12, 2017

Theraclion Reports Positive Long-Term Echopulse Results in Breast Fibroadenoma

Study results reveal mean volume reduction at 24 months; treatment is safe and well-tolerated by patients

April 12, 2017 — Theraclion announced results of a study evaluating the long-term assessment of breast fibroadenoma (benign tumor) volume reduction following treatment with the company’s Echopulse, a non-invasive treatment employing ultrasound-guided high-intensity focused ultrasound. The study, entitled “Long-term efficacy of ultrasound-guided high-intensity focused ultrasound (US-guided HIFU) treatment of breast fibroadenoma,” was published online in the March 2017 issue of the Journal of Therapeutic Ultrasound and is available online.

The study assessed a total of 20 female patients with 26 breast fibroadenomas (BFAs) before and for up to 24 months following echotherapy treatment with Echopulse. Nineteen BFAs received a single treatment and seven BFAs a second treatment six to nine months after the initial session. BFA volume was measured by ultrasound. Patient satisfaction on cosmetic results and symptom relief were surveyed and safety and tolerability was recorded. The study demonstrated consistent echotherapy results confirmed at 24 months:

  • Mean BFA volume was significantly reduced by 77.32 percent after a single procedure and by 90.47 percent after two procedures at 24 months follow up;
  • No cases of re-growth of treated lesions were observed during the 24 months follow-up;
  • Treatment was very well-tolerated regardless of whether one or two echotherapy sessions were performed. Side effects were mild and transient and resolved completely; no serious side effects were observed;
  • Of the 20 patients who completed a satisfaction survey, all 20 (100 percent) were completely or highly satisfied with the cosmetic results and 19 of 20 (95 percent) were completely or highly satisfied concerning symptom disappearance; and
  • Authors concluded that “US-guided HIFU represents a promising non-invasive method with sustainable FA volume reduction and patient’s tolerability. Although one treatment is highly efficient, the volume reduction can be increased with second treatment.”

Roussanka Kovatcheva, M.D., professor of endocrinology at the University Hospital of Endocrinology of Sofia, Bulgaria, and Principal Investigator said, “Our results show the long-term efficacy and safety of US-guided HIFU generated by Theraclion’s Echopulse in patients with breast fibroadenomas. US-guided HIFU is definitely an effective non-invasive alternative to surgery enabling more than 90 percent volume reduction without re-growth or serious adverse events.”

For more information: www.jtultrasound.biomedcentral.com

Related Content

Machine Learning IDs Markers to Help Predict Alzheimer's

Neurologists use structural and diffusion magnetic resonance imaging (MRI) to identify changes in brain tissue (both gray and white matter) that are characteristic of Alzheimer's disease and other forms of dementia. The MRI images are analyzed using morphometry and tractography techniques, which detect changes in the shape and dimensions of the brain and in the tissue microstructure, respectively. In this example, the images show the normal brain of an elderly patient. Image courtesy of Jiook Cha.

News | Neuro Imaging | September 20, 2018
New research has shown a combination of two different modes of magnetic resonance imaging (MRI), computer-based...
breast screening
News | Clinical Trials | September 13, 2018
Fewer and fewer women die from breast cancer in recent years but, surprisingly, the decline is just as large in the a
Lightvision near-infrared fluorescence imaging system
News | Women's Health | September 11, 2018
Shimadzu Corp.
Feature | Breast Imaging | September 07, 2018 | By JoAnn Pushkin
If you are confused about the conflicting advice surrounding mammography screening guidelines, welcome to the club.
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...
Check-Cap Announces Interim Results of European Study of C-Scan System Version 3
News | Colonoscopy Systems | September 04, 2018
Check-Cap Ltd. announced the interim results for its post-CE approval study of the C-Scan system Version 3, an...
Brain Iron Levels May Predict Multiple Sclerosis Disabilities
News | Neuro Imaging | August 31, 2018
A new, highly accurate magnetic resonance imaging (MRI) technique can monitor iron levels in the brains of multiple...
Study Finds Multiple Sclerosis Drug Slows Brain Shrinkage

An NIH-funded clinical trial suggested that the anti-inflammatory drug ibudilast may slow brain shrinkage caused by progressive MS. Image courtesy of Robert J. Fox, M.D., Cleveland Clinic.

News | Neuro Imaging | August 30, 2018
August 30, 2018 — Results from a clinical...
Rapid Cardiac MRI Technique May Cut Costs, Boost Care in Developing World
News | Magnetic Resonance Imaging (MRI) | August 29, 2018
A newly developed rapid imaging protocol quickly and cheaply diagnosed heart ailments in patients in Peru, according to...